Literature DB >> 11292837

Genetic evidence for the involvement of DNA ligase IV in the DNA-PK-dependent pathway of non-homologous end joining in mammalian cells.

H Wang1, Z C Zeng, A R Perrault, X Cheng, W Qin, G Iliakis.   

Abstract

Cells of vertebrates remove DNA double-strand breaks (DSBs) from their genome predominantly utilizing a fast, DNA-PKcs-dependent form of non-homologous end joining (D-NHEJ). Mutants with inactive DNA-PKcs remove the majority of DNA DSBs utilizing a slow, DNA-PKcs-independent pathway that does not utilize genes of the RAD52 epistasis group, is error-prone and can therefore be classified as a form of NHEJ (termed basic or B-NHEJ). We studied the role of DNA ligase IV in these pathways of NHEJ. Although biochemical studies show physical and functional interactions between the DNA-PKcs/Ku and the DNA ligase IV/Xrcc4 complexes suggesting operation within the same pathway, genetic evidence to support this notion is lacking in mammalian cells. Primary human fibroblasts (180BR) with an inactivating mutation in DNA ligase IV, rejoined DNA DSBs predominantly with slow kinetics similar to those observed in cells deficient in DNA-PKcs, or in wild-type cells treated with wortmannin to inactivate DNA-PK. Treatment of 180BR cells with wortmannin had only a small effect on DNA DSB rejoining and no effect on cell radiosensitivity to killing although it sensitized control cells to 180BR levels. This is consistent with DNA ligase IV functioning as a component of the D-NHEJ, and demonstrates the unperturbed operation of the DNA-PKcs-independent pathway (B-NHEJ) at significantly reduced levels of DNA ligase IV. In vitro, extracts of 180BR cells supported end joining of restriction endonuclease-digested plasmid to the same degree as extracts of control cells when tested at 10 mM Mg(2+). At 0.5 mM Mg(2+), where only DNA ligase IV is expected to retain activity, low levels of end joining ( approximately 10% of 10 mM) were seen in the control but there was no detectable activity in 180BR cells. Antibodies raised against DNA ligase IV did not measurably inhibit end joining at 10 mM Mg(2+) in either cell line. Thus, in contrast to the situation in vivo, end joining in vitro is dominated by pathways with properties similar to B-NHEJ that do not display a strong dependence on DNA ligase IV, with D-NHEJ retaining only a limited contribution. The implications of these observations to studies of NHEJ in vivo and in vitro are discussed.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2001        PMID: 11292837      PMCID: PMC31316          DOI: 10.1093/nar/29.8.1653

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  64 in total

1.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction.

Authors:  M P Wymann; G Bulgarelli-Leva; M J Zvelebil; L Pirola; B Vanhaesebroeck; M D Waterfield; G Panayotou
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

2.  DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product.

Authors:  K O Hartley; D Gell; G C Smith; H Zhang; N Divecha; M A Connelly; A Admon; S P Lees-Miller; C W Anderson; S P Jackson
Journal:  Cell       Date:  1995-09-08       Impact factor: 41.582

3.  Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells.

Authors:  U Grawunder; M Wilm; X Wu; P Kulesza; T E Wilson; M Mann; M R Lieber
Journal:  Nature       Date:  1997-07-31       Impact factor: 49.962

4.  The scid defect results in much slower repair of DNA double-strand breaks but not high levels of residual breaks.

Authors:  B Nevaldine; J A Longo; P J Hahn
Journal:  Radiat Res       Date:  1997-05       Impact factor: 2.841

5.  Repair of x-ray-induced DNA double-strand breaks in specific Not I restriction fragments in human fibroblasts: joining of correct and incorrect ends.

Authors:  M Löbrich; B Rydberg; P K Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

6.  Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates.

Authors:  C Zhu; M A Bogue; D S Lim; P Hasty; D B Roth
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

7.  Requirement for Ku80 in growth and immunoglobulin V(D)J recombination.

Authors:  A Nussenzweig; C Chen; V da Costa Soares; M Sanchez; K Sokol; M C Nussenzweig; G C Li
Journal:  Nature       Date:  1996-08-08       Impact factor: 49.962

8.  Molecular cloning and expression of human cDNAs encoding a novel DNA ligase IV and DNA ligase III, an enzyme active in DNA repair and recombination.

Authors:  Y F Wei; P Robins; K Carter; K Caldecott; D J Pappin; G L Yu; R P Wang; B K Shell; R A Nash; P Schär
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

9.  DNA ligase IV from HeLa cell nuclei.

Authors:  P Robins; T Lindahl
Journal:  J Biol Chem       Date:  1996-09-27       Impact factor: 5.157

10.  Radiation-induced DNA damage and repair in cells of a radiosensitive human malignant glioma cell line.

Authors:  M J Allalunis-Turner; P K Zia; G M Barron; R Mirzayans; R S Day
Journal:  Radiat Res       Date:  1995-12       Impact factor: 2.841

View more
  34 in total

Review 1.  Somatic hypermutation in human B cell subsets.

Authors:  N S Longo; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  Biochemical evidence for Ku-independent backup pathways of NHEJ.

Authors:  Huichen Wang; Ange Ronel Perrault; Yoshihiko Takeda; Wei Qin; Hongyan Wang; George Iliakis
Journal:  Nucleic Acids Res       Date:  2003-09-15       Impact factor: 16.971

3.  An xrcc4 defect or Wortmannin stimulates homologous recombination specifically induced by double-strand breaks in mammalian cells.

Authors:  Fabien Delacôte; Mingguang Han; Thomas D Stamato; Maria Jasin; Bernard S Lopez
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

4.  Patching and single-strand ligation in nonhomologous DNA end joining despite persistence of a closely opposed 3'-phosphoglycolate-terminated strand break.

Authors:  Rui-Zhe Zhou; Konstantin Akopiants; Lawrence F Povirk
Journal:  Radiat Res       Date:  2010-09       Impact factor: 2.841

5.  PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF.

Authors:  Parker L Sulkowski; Susan E Scanlon; Sebastian Oeck; Peter M Glazer
Journal:  Mol Cancer Res       Date:  2018-05-08       Impact factor: 5.852

6.  Kinetic analysis of the Ku-DNA binding activity reveals a redox-dependent alteration in protein structure that stimulates dissociation of the Ku-DNA complex.

Authors:  Brooke J Andrews; Jason A Lehman; John J Turchi
Journal:  J Biol Chem       Date:  2006-03-13       Impact factor: 5.157

7.  The mTOR inhibitor rapamycin suppresses DNA double-strand break repair.

Authors:  Honghong Chen; Zhefu Ma; Robert P Vanderwaal; Zhihui Feng; Ignacio Gonzalez-Suarez; Shenming Wang; Jiuqin Zhang; Joseph L Roti Roti; Susana Gonzalo; Junran Zhang
Journal:  Radiat Res       Date:  2010-10-26       Impact factor: 2.841

8.  Localized movement and morphology of UBF1-positive nucleolar regions are changed by γ-irradiation in G2 phase of the cell cycle.

Authors:  Dmitry V Sorokin; Lenka Stixová; Petra Sehnalová; Soňa Legartová; Jana Suchánková; Pavel Šimara; Stanislav Kozubek; Pavel Matula; Magdalena Skalníková; Ivan Raška; Eva Bártová
Journal:  Nucleus       Date:  2015-07-24       Impact factor: 4.197

9.  Involvement of p54(nrb), a PSF partner protein, in DNA double-strand break repair and radioresistance.

Authors:  Shuyi Li; Wendy W Kuhne; Anita Kulharya; Farlyn Z Hudson; Kyungsoo Ha; Zhen Cao; William S Dynan
Journal:  Nucleic Acids Res       Date:  2009-09-16       Impact factor: 16.971

10.  Molecular analysis of Ku redox regulation.

Authors:  Sara M Bennett; Tracy M Neher; Andrea Shatilla; John J Turchi
Journal:  BMC Mol Biol       Date:  2009-08-28       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.